Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy BioPharma DiveNews of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. Neuroscience Read full story Post navigation Previous: Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchNext: Parexel buys Vitrana to boost patient safety toolkit Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026